REG - Yourgene Health PLC - Admission of Company Considerations Shares and TVR

Yourgene HealthAnnouncement

11/08/2020 07:00

RNS Number : 7092V
  
Yourgene Health PLC
  
11 August 2020
  
 

 
Yourgene Health plc
("Yourgene" or the "Group" or the "Company")
 
Confirmation of the admission of Company Considerations Shares and Total Voting Rights 
 
Manchester, UK - 11 August 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that, following the admission of 95,000,000 Placing Shares on 7 August 2020, the Acquisition, as announced by the Company on 4 August 2020, became unconditional in all respects on Friday 7 August 2020.  
 
Total Voting Rights
The 178,753 Company Consideration Shares will be admitted to trading on AIM at 8am today.  Following admission of the Company Consideration Shares, the Company's issued and fully paid share capital will consist of 719,509,950 Ordinary Shares.  This figure of 719,509,950 Ordinary Shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
 
ExchangeCo Shares
As detailed in the announcement of the Company dated 4 August 2020,  10,249,624  new shares in Yourgene Health Canada Investments Ltd, a subsidiary of Yourgene Health plc, incorporated under the laws of British Columbia, Canada (the "ExchangeCo Shares") were issued to certain of the Sellers on completion of the Acquisition on 7 August 2020.
 
The ExchangeCo Shares do not carry voting rights, but entitle the holders thereof to participate in any Group dividends on an equivalent basis and are capable of being exchanged for Ordinary Shares in the Company at a price of 18.3 pence per Ordinary Share, subject to lock-in restrictions.
 
Correction: Participation by Directors in the Placing
As announced on the 5 August 2020, certain of the Company's Directors (including Dr. Bill Chang, who is also a substantial shareholder) agreed to subscribe for Placing Shares at the Placing Price. The number of existing Ordinary shares, number of Ordinary shares held at Admission and the percentage of enlarged share capital on Admission were detailed incorrectly for Dr. Bill Chang.
 
The corrected number of Placing Shares subscribed for by Dr. Bill Chang pursuant to the Placing, and the resulting shareholdings on Admission is set out below:
 



Director


Number of existing Ordinary Shares


Number of Placing Shares subscribed for in the Placing


Number of Ordinary Shares held

on Admission


Percentage of enlarged

share capital on Admission




Dr. Bill Chang


                        79,490,142 


                  510,000 


            80,000,142 


11.1%



 
Definitions
Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the announcement released by the Company at 5.13pm on 4 August 2020.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
 



Yourgene Health plc
Lyn Rees, Chief Executive Officer


Tel: +44 (0)161 669 8122
investors@yourgene-health.com




Barry Hextall, Chief Financial Officer


 




Joanne Cross, Director of Marketing


 




 


 




 


 




Cairn Financial Advisers LLP (NOMAD)


Tel: +44 (0)20 7213 0880




Liam Murray / James Caithie / Ludovico Lazzaretti


















N+1 Singer (Joint Corporate Broker)


Tel: +44 (0)20 7496 3000




Aubrey Powell / Tom Salvesen / George Tzimas


 




 


 




Stifel Nicolaus Europe Limited (Joint Corporate Broker)


Tel: +44 (0)20 7710 7600




Nicholas Moore / Matthew Blawat / Ben Maddison


 




 


 




 


 




Walbrook PR Ltd (Media and Investor Relations)


Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com




 Paul McManus / Lianne Cawthorne


Mob: 07980 541 893 / Mob: 07584 391 303  




 


 


 









 
 
About Yourgene Health plc
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, for reproductive health and precision medicine. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
 
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene is also extending its genetic testing offering into oncology.
 
Yourgene is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information, visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCEAPPEFDAEEFA